Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Brescia – page 65

902 clinical trials in Brescia, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Brescia at a glance
902
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

902 trials in Brescia

Open in trial search

Plasma cell myeloma

Not recruiting

Study on the Effectiveness and Safety of Cevostamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab with Drug Combination for Young Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Ceska Myelomova Skupina z.s.

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Acute myeloid leukaemia

Not recruiting

Study of venetoclax and azacitidine treatment in adults with NPM1-mutated acute myeloid leukemia who experience molecular relapse or disease progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib
  • Sponsor:Loxo Oncology Inc.

Acute lymphocytic leukaemia

Not recruiting

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Acute myeloid leukaemia (in remission)

Not recruiting

Study on the Effectiveness of Decitabine and Venetoclax for Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Myasthenia gravis

Not recruiting

Study on the Effectiveness and Safety of Batoclimab for Adults with Generalized Myasthenia Gravis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

C3 glomerulopathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Complement 3 Glomerulopathy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Brescia

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on metastatic colorectal cancer, chronic myeloid leukemia, and renal cell carcinoma. Studies evaluate novel combination therapies and treatment strategies for advanced cancer cases.

  • Colorectal Cancer Treatment
  • Leukemia Therapies
  • Advanced Renal Cancer

Research includes evaluation of targeted therapies and immunotherapy approaches.

02 Neurological Disorders

Comprehensive studies addressing Parkinson's disease, Frontotemporal Dementia, and Alzheimer's-related psychosis. Research focuses on novel therapeutic approaches and disease-modifying treatments.

  • Early-Stage Parkinson's Treatment
  • Dementia Management
  • Neurological Drug Development

Trials aim to improve patient outcomes and quality of life.

03 Autoimmune Conditions

Groundbreaking research in Psoriatic Arthritis, Crohn's Disease, and Sjögren's Syndrome. Studies evaluate biological therapies and innovative treatment approaches.

  • Inflammatory Disease Management
  • Autoimmune Response Modulation
  • Novel Therapeutic Approaches

Focus on developing targeted treatments for chronic conditions.

04 Cardiovascular Research

Studies addressing heart failure prevention and cardiovascular disease. Research evaluates new combination therapies and preventive approaches.

  • Heart Failure Prevention
  • Cardiovascular Risk Reduction
  • Therapeutic Combinations

Emphasis on preventive strategies and innovative treatments.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.